Smokers in Kerala spends 226 crore on cardiovascular treatment
Advertisement
According to a recent study published by the Public Health Foundation of India, the population of smokers in Kerala is stated to be spending high on availing treatment for cardiovascular diseases; the amount concluded is a staggering Rs.226 crore.
The report is based on a one-year study on 'Economic Burden of Tobacco Related Diseases in India' conducted by the Public Health Foundation of India with support from the union ministry of health and family welfare, and the World Health Organization.
The amount was the aggregate of four major tobacco-induced ailments in Kerala, contributing to 51 percent of total direct medical costs.
The report covers both direct medical costs and indirect morbidity costs of four specific diseases - cardiovascular diseases, cancer, tuberculosis, and respiratory diseases.
In another significant conclusion of the fact that the total direct medical cost from tobacco-induced cardiovascular diseases in Kerala is also the highest among south Indian states, has been stated in a separate recent report.
The direct medical cost from tobacco-related heart diseases in neighbouring Tamil Nadu is 46 percent, while that in Andhra Pradesh and Karnataka it is respectively 48 and 40 percent.
The study, whose results were released on Monday, estimated the economic costs for people in the age group of 35-69 in 2011.
Direct medical costs include patients' healthcare expenditure in hospitals or visits to outpatient facilities for medicines, diagnostic tests, and surgeon's or medic's fees.
Indirect costs accrue from expenses on transportation, lodging for caregivers and loss of household income due to hospitalisation, besides costs from premature deaths.
The economic burden study has suggested a host of measures to deal with the tobacco menace. These include strengthening the implementation of Indian tobacco control laws and imposing uniform taxes on all tobacco products like cigarettes and bidis.
It has also recommended prohibition of sale and manufacture of all forms of smokeless tobacco products/chewable tobacco, and push for high-visibility public awareness campaigns to consistently reach out to various target audience.
The report is based on a one-year study on 'Economic Burden of Tobacco Related Diseases in India' conducted by the Public Health Foundation of India with support from the union ministry of health and family welfare, and the World Health Organization.
The amount was the aggregate of four major tobacco-induced ailments in Kerala, contributing to 51 percent of total direct medical costs.
The report covers both direct medical costs and indirect morbidity costs of four specific diseases - cardiovascular diseases, cancer, tuberculosis, and respiratory diseases.
In another significant conclusion of the fact that the total direct medical cost from tobacco-induced cardiovascular diseases in Kerala is also the highest among south Indian states, has been stated in a separate recent report.
The direct medical cost from tobacco-related heart diseases in neighbouring Tamil Nadu is 46 percent, while that in Andhra Pradesh and Karnataka it is respectively 48 and 40 percent.
The study, whose results were released on Monday, estimated the economic costs for people in the age group of 35-69 in 2011.
Direct medical costs include patients' healthcare expenditure in hospitals or visits to outpatient facilities for medicines, diagnostic tests, and surgeon's or medic's fees.
Indirect costs accrue from expenses on transportation, lodging for caregivers and loss of household income due to hospitalisation, besides costs from premature deaths.
The economic burden study has suggested a host of measures to deal with the tobacco menace. These include strengthening the implementation of Indian tobacco control laws and imposing uniform taxes on all tobacco products like cigarettes and bidis.
It has also recommended prohibition of sale and manufacture of all forms of smokeless tobacco products/chewable tobacco, and push for high-visibility public awareness campaigns to consistently reach out to various target audience.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.